Enterprise Value
1.037B
Cash
973.7M
Avg Qtr Burn
-108.7M
Short % of Float
0.01%
Insider Ownership
0.00%
Institutional Own.
3.18%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TARPEYO (Nefecon) (budesonide) Details IgA nephropathy | Approved Quarterly sales | |
TARPEYO (Nefecon) (budesonide) Details IgA nephropathy | Approved Quarterly sales | |
Setanaxib (NOX1/NOX4 inhibitor) Details Primary biliary cholangitis, Liver disease | Phase 2/3 Data readout | |
Setanaxib (NOX1/NOX4 inhibitor) Details Alport Syndrome | Phase 2 Data readout | |
Setanaxib (NOX1/NOX4 inhibitor) Details Idiopathic pulmonary fibrosis | Phase 2 Data readout | |
Setanaxib (NOX1/NOX4 inhibitor) Details Cancer, Solid tumor/s, Head and neck squamous cell carcinoma | Phase 2 Data readout |